Animal study · Supplements / medicine · 19 Nov 2026
In mice, an experimental compound raised energy use and spared lean mass; human tests are still ahead
Source: Science Advances
What the research found
A Science Advances paper from UC Berkeley reports mouse experiments with 5-tetradecyloxy-2-furoic acid, called TOFA. In obese mice the compound raised energy expenditure by as much as 18 percent without more movement or a higher body temperature. The mice lost fat, insulin sensitivity improved, triglycerides fell, and liver fat improved, without a large loss of lean mass. TOFA slows fatty-acid production and also turns on PPARα and PPARδ, receptors that help cells take up and burn fat. Other drugs that only block the same enzyme have raised triglycerides in earlier work. TOFA did not do that in these mice. Combining it with semaglutide or tirzepatide, in mice, changed weight and glucose more than either approach alone. The authors describe that as a complement, not a replacement. Safety and effect in humans are not known. The Berkeley group has started a company, ReRx Therapeutics, and one author lists that affiliation. The paper cites university support, including UC Berkeley, the UCSF Liver Center, and a Michigan phenotyping core. DOI 10.1126/sciadv.aed3119. Not medical advice.
Evidence level: Animal study. Results in animals or cells often don't carry over to people.
Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
More supplements / medicine news
- In mice, imeglimin lined up with less islet injury after transplant; human islets have not been tested
- In two phase 3 trials, retatrutide lined up with large weight loss and less knee pain, and joint damage was not shown to stop
- In 720 patients with facial palsy, vitamin B12, vitamin D, protein intake, and a low index lined up with incomplete recovery
- Across 16 studies and 5,679 older adults, a higher medication burden lined up with higher odds of sarcopenia
- Across 64 Middle East and North Africa trials, intermediate vitamin D doses raised 25(OH)D, and higher doses added less